
Sensient Technologies Corporation Reports Results for the Quarter Ended March 31, 2025
First Quarter Consolidated Results
Reported revenue increased 2.0% to $392.3 million in the first quarter of 2025 versus last year's first quarter results of $384.7 million. On a local currency basis (1), revenue increased 4.1%.
Reported operating income increased 8.3% to $53.5 million compared to $49.4 million recorded in the first quarter of 2024. In the first quarter of 2025, the Company recorded $2.9 million of costs related to its Portfolio Optimization Plan versus last year's $2.8 million in the first quarter. Local currency adjusted operating income (1) and local currency adjusted EBITDA (1) increased 10.3% and 10.1%, respectively, in the first quarter.
Reported earnings per share increased 11.0% to 81 cents in the first quarter of 2025 compared to 73 cents in the first quarter of 2024. Local currency adjusted diluted EPS (1) increased 11.4% in the first quarter.
'As expected, Sensient got off to a strong start in the first quarter of 2025, building on the momentum from the previous year. Our results are driven by solid volume growth and sales wins, particularly in natural colors. The quarter's achievements underscore our ability to adapt in dynamic market conditions, and I am pleased to reaffirm our 2025 guidance,' said Paul Manning, Sensient's Chairman, President, and Chief Executive Officer.
The Flavors & Extracts Group reported first quarter 2025 revenue of $193.7 million, an increase of $0.6 million versus the prior year's first quarter. The Group's revenue benefited from higher volumes in our flavors, extracts, and flavor ingredients product lines, offset by lower volumes in natural ingredients. Segment operating income was $25.0 million in the first quarter of 2025, an increase of $1.3 million compared to the prior year's first quarter.
The Color Group reported revenue of $167.8 million in the first quarter of 2025, an increase of $7.7 million compared to the prior year's first quarter. The Group's revenue increase was broad-based across all product lines. Segment operating income was $34.9 million in the first quarter of 2025, an increase of $3.2 million compared to the prior year's first quarter results.
The Asia Pacific Group reported revenue of $41.9 million in the first quarter of 2025, an increase of $1.6 million compared to the prior year's first quarter. The Group's revenue increased across nearly all geographies. Segment operating income was $9.4 million in the quarter, an increase of $0.7 million compared to the prior year's first quarter.
Corporate & Other reported operating expenses of $15.8 million in the first quarter of 2025, compared to $14.7 million of operating expenses reported in the prior year's first quarter. Local currency adjusted operating expenses (1) for Corporate & Other increased $1.0 million compared to the prior year's first quarter, primarily due to higher performance-based compensation costs recorded in 2025.
The Company's guidance is based on current conditions and economic and market trends in the markets in which the Company operates and is subject to various risks and uncertainties as described below.
USE OF NON-GAAP FINANCIAL MEASURES
The Company's non-GAAP financial measures eliminate the impact of certain items, which, depending on the measure, include: currency movements, depreciation and amortization, Portfolio Optimization Plan costs, and non-cash share-based compensation. These measures are provided to enhance the overall understanding of the Company's performance when viewed together with the GAAP results. Refer to ' Reconciliation of Non-GAAP Amounts ' at the end of this release.
CONFERENCE CALL
The Company will host a conference call to discuss its 2025 first quarter financial results at 8:30 a.m. CDT on Friday, April 25, 2025. To participate in the conference call, contact Chorus Call Inc. at (844) 492-3726 or (412) 317-1078, and ask to join the Sensient Technologies Corporation conference call. Alternatively, the call can be accessed by using the webcast link that is available on the Investor Information section of the Company's web site at www.sensient.com.
A replay of the call will be available one hour after the end of the conference call through May 2, 2025, by calling (877) 344-7529 and using access code 4206177. An audio replay and written transcript of the call will also be posted on the Investor Information section of the Company's web site at www.sensient.com on or after April 29, 2025.
This release contains statements that may constitute 'forward-looking statements' within the meaning of Federal securities laws including under '2025 Outlook' above. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors concerning the Company's operations and business environment. Important factors that could cause actual results to differ materially from those suggested by these forward-looking statements and that could adversely affect the Company's future financial performance include the following: the Company's ability to manage general business, economic, and capital market conditions, including actions taken by customers in response to such market conditions, and the impact of recessions and economic downturns; the impact of macroeconomic and geopolitical volatility, including inflation and shortages impacting the availability and cost of raw materials, energy, and other supplies, disruptions and delays in the Company's supply chain, and the conflicts between Russia and Ukraine and in the Middle East; industry, regulatory, legal, and economic factors related to the Company's domestic and international business; the effects of tariffs, trade barriers, and disputes; the availability and cost of labor, logistics, and transportation; the pace and nature of new product introductions by the Company and the Company's customers; the Company's ability to anticipate and respond to changing consumer preferences, changing technologies, and changing regulations; the Company's ability to successfully implement its growth strategies; the outcome of the Company's various productivity-improvement and cost-reduction efforts, acquisition and divestiture activities, and Portfolio Optimization Plan; growth in markets for products in which the Company competes; industry and customer acceptance of price increases; actions by competitors; the Company's ability to enhance its innovation efforts and drive cost efficiencies; currency exchange rate fluctuations; and other factors included in 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and in other documents that the Company files with the SEC. The risks and uncertainties identified above are not the only risks the Company faces. Additional risks and uncertainties not presently known to the Company or that it currently believes to be immaterial also may adversely affect the Company. Should any known or unknown risks and uncertainties develop into actual events, these developments could have material adverse effects on our business, financial condition, and results of operations. This release contains time-sensitive information that reflects management's best analysis only as of the date of this release. Except to the extent required by applicable laws, the Company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied herein will not be realized.
ABOUT SENSIENT TECHNOLOGIES
Sensient Technologies Corporation is a leading global manufacturer and marketer of colors, flavors, and other specialty ingredients. Sensient uses advanced technologies and robust global supply chain capabilities to develop specialized solutions for food and beverages, as well as products that serve the pharmaceutical, nutraceutical, and personal care industries. Sensient's customers range in size from small entrepreneurial businesses to major international manufacturers representing some of the world's best-known brands. Sensient is headquartered in Milwaukee, Wisconsin.
Sensient Technologies Corporation
(In thousands)
(Unaudited)
Consolidated Condensed Balance Sheets
March 31,
December 31,
2025
2024
Cash and cash equivalents
$
32,574
$
26,626
Trade accounts receivable
315,024
290,087
Inventories
598,204
600,302
Prepaid expenses and other current assets
54,407
44,871
Total Current Assets
1,000,209
961,886
Goodwill & intangible assets (net)
435,681
423,658
Property, plant, and equipment (net)
499,184
491,587
Other assets
157,594
146,663
Total Assets
$
2,092,668
$
2,023,794
Trade accounts payable
$
110,611
$
139,052
Short-term borrowings
18,575
19,848
Other current liabilities
101,509
111,739
Total Current Liabilities
230,695
270,639
Long-term debt
683,266
613,523
Accrued employee and retiree benefits
25,175
24,499
Other liabilities
58,498
54,147
Shareholders' Equity
1,095,034
1,060,986
Total Liabilities and Shareholders' Equity
$
2,092,668
$
2,023,794
Expand
Sensient Technologies Corporation
(In thousands, except per share amounts)
(Unaudited)
Consolidated Statements of Cash Flows
Three Months Ended March 31,
2025
2024
Cash flows from operating activities:
Net earnings
$
34,462
$
30,940
Adjustments to arrive at net cash provided by operating activities:
Depreciation and amortization
15,074
14,709
Share-based compensation expense
2,900
1,995
Net loss (gain) on assets
46
(193
)
Portfolio Optimization Plan costs
831
1,189
Deferred income taxes
1,282
(4
)
Changes in operating assets and liabilities:
Trade accounts receivable
(20,780
)
(28,331
)
Inventories
7,202
26,624
Prepaid expenses and other assets
(8,064
)
(13,655
)
Trade accounts payable and other accrued expenses
(25,859
)
(21,993
)
Accrued salaries, wages, and withholdings
(21,665
)
29
Income taxes
4,989
3,150
Other liabilities
604
674
Net cash (used in) provided by operating activities
(8,978
)
15,134
Cash flows from investing activities:
Acquisition of property, plant, and equipment
(16,854
)
(11,030
)
Proceeds from sale of assets
7
93
Acquisition of new business
(4,349
)
-
Other investing activities
(88
)
(1
)
Net cash used in investing activities
(21,284
)
(10,938
)
Cash flows from financing activities:
Proceeds from additional borrowings
66,449
38,053
Debt payments
(10,771
)
(27,031
)
Dividends paid
(17,376
)
(17,312
)
Other financing activities
(2,341
)
(2,828
)
Net cash provided by (used in) financing activities
35,961
(9,118
)
Effect of exchange rate changes on cash and cash equivalents
249
1,405
Net increase (decrease) in cash and cash equivalents
5,948
(3,517
)
Cash and cash equivalents at beginning of period
26,626
28,934
Cash and cash equivalents at end of period
$
32,574
$
25,417
Supplemental Information
Three Months Ended March 31,
2025
2024
Dividends paid per share
$
0.41
$
0.41
Expand
Sensient Technologies Corporation
(In thousands, except percentages and per share amounts)
(Unaudited)
Reconciliation of Non-GAAP Amounts
The Company's results for the three months ended March 31, 2025 and 2024 include adjusted operating income, adjusted net earnings, and adjusted diluted earnings per share, which, in each case, exclude Portfolio Optimization Plan costs.
Three Months Ended March 31,
2025
2024
% Change
Operating income (GAAP)
$
53,530
$
49,406
8.3
%
Portfolio Optimization Plan costs – Cost of products sold
1,814
107
Portfolio Optimization Plan costs – Selling and administrative
expenses
1,050
2,705
Adjusted operating income
$
56,394
$
52,218
8.0
%
Net earnings (GAAP)
$
34,462
$
30,940
11.4
%
Portfolio Optimization Plan costs, before tax
2,864
2,812
Tax impact of Portfolio Optimization Plan costs (1)
(702
)
(355
)
Adjusted net earnings
$
36,624
$
33,397
9.7
%
Diluted earnings per share (GAAP)
$
0.81
$
0.73
11.0
%
Portfolio Optimization Plan costs, net of tax
0.05
0.06
Adjusted diluted earnings per share
$
0.86
$
0.79
8.9
%
Note: Earnings per share calculations may not foot due to rounding differences.
(1) Tax impact adjustments were determined based on the nature of the underlying non-GAAP adjustments and their relevant jurisdictional tax rates.
Results by Segment
Three Months Ended March 31,
Adjusted
Adjusted
Operating Income
2025
Adjustments (2)
2025
2024
Adjustments (2)
2024
Flavors & Extracts
$
24,989
$
-
$
24,989
$
23,678
$
-
$
23,678
Color
34,852
-
34,852
31,679
-
31,679
Asia Pacific
9,442
-
9,442
8,776
-
8,776
Corporate & Other
(15,753
)
2,864
(12,889
)
(14,727
)
2,812
(11,915
)
Consolidated
$
53,530
$
2,864
$
56,394
$
49,406
$
2,812
$
52,218
(2) Adjustments consist of Portfolio Optimization Plan costs.
The following table summarizes the percentage change in the 2025 results compared to the 2024 results for the corresponding periods.
Three Months Ended March 31, 2025
Revenue Total Foreign
Exchange
Rates Adjustments (3) Local
Currency
Adjusted
Flavors & Extracts
0.3
%
(1.4
%)
N/A
1.7
%
Color
4.8
%
(3.4
%)
N/A
8.2
%
Asia Pacific
4.0
%
(0.8
%)
N/A
4.8
%
Total Revenue
2.0
%
(2.1
%)
N/A
4.1
%
Operating Income
Flavors & Extracts
5.5
%
(0.7
%)
0.0
%
6.2
%
Color
10.0
%
(3.5
%)
0.0
%
13.5
%
Asia Pacific
7.6
%
0.6
%
0.0
%
7.0
%
Corporate & Other
7.0
%
0.0
%
(1.2
%)
8.2
%
Total Operating Income
8.3
%
(2.5
%)
0.5
%
10.3
%
Diluted Earnings Per Share
11.0
%
(2.7
%)
2.3
%
11.4
%
Adjusted EBITDA
7.9
%
(2.2
%)
N/A
10.1
%
(3) Adjustments consist of Portfolio Optimization Plan costs.
Expand
Sensient Technologies Corporation
(In thousands, except percentages)
(Unaudited)
Reconciliation of Non-GAAP Amounts - Continued
The following table summarizes the reconciliation between Operating Income (GAAP) and Adjusted EBITDA for the three months ended March 31, 2025 and 2024.
Three Months Ended March 31,
2025
2024
% Change
Operating income (GAAP)
$
53,530
$
49,406
8.3
%
Depreciation and amortization
15,074
14,709
Share-based compensation expense
2,900
1,995
Portfolio Optimization Plan costs, before tax
2,864
2,812
Adjusted EBITDA
$
74,368
$
68,922
7.9
%
The following table summarizes the reconciliation between Debt (GAAP) and Net Debt, and Operating Income (GAAP) and Credit Adjusted EBITDA for the trailing twelve months ended March 31, 2025 and 2024.
March 31,
Debt
2025
2024
Short-term borrowings
$
18,575
$
19,439
Long-term debt
683,266
643,511
Credit Agreement adjustments (4)
(21,165
)
(13,775
)
Net Debt
$
680,676
$
649,175
Operating income (GAAP)
$
195,703
$
153,591
Depreciation and amortization
60,694
58,379
Share-based compensation expense
10,989
8,661
Portfolio Optimization Plan costs, before tax
6,683
30,653
Other non-operating gains (5)
(871
)
(1,055
)
Credit Adjusted EBITDA
$
273,198
$
250,229
Net Debt to Credit Adjusted EBITDA 2.5x 2.6x
(4) Adjustments include cash and cash equivalents, as described in the Company's Third Amended and Restated Credit Agreement (Credit Agreement), and certain letters of credit and hedge contracts.
(5) Adjustments consist of certain financing transaction costs, certain non-financing interest items, and gains and losses related to certain non-cash, non-operating, and/or non-recurring items as described in the Credit Agreement.
We have included each of these non-GAAP measures in order to provide additional information regarding our underlying operating results and comparable period-over-period performance. Such information is supplemental to information presented in accordance with GAAP and is not intended to represent a presentation in accordance with GAAP. These non-GAAP measures should not be considered in isolation. Rather, they should be considered together with GAAP measures and the rest of the information included in this release and our SEC filings. Management internally reviews each of these non-GAAP measures to evaluate performance on a comparative period-to-period basis and to gain additional insight into underlying operating and performance trends, and we believe the information can be beneficial to investors for the same purposes. These non-GAAP measures may not be comparable to similarly titled measures used by other companies.
Expand
Category: Earnings
Source: Sensient Technologies Corporation
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Smarsh Named to Inc. 5000 for 18th Consecutive Year
Prestigious annual ranking of the most successful private companies in America spotlights 3-year revenue growth of 114% at Smarsh PORTLAND, Ore., August 12, 2025--(BUSINESS WIRE)--Smarsh, the global leader in digital communications compliance and intelligence, today announced it has been named to the Inc. 5000 list of the fastest-growing private companies in America for the 18th year in a row. This remarkable achievement underscores nearly two decades of sustained growth, innovation, and customer impact in one of the most essential and rapidly evolving sectors of enterprise technology. Smarsh is one of only two organizations in the history of the Inc. 5000 to receive this recognition 18 times. Where Vision Meets Execution "Smarsh is honored to be recognized on the Inc. 5000 list for the eighteenth consecutive year," said Kim Crawford Goodman, Chief Executive Officer of Smarsh. "This achievement reflects how we've redefined sustainable growth and delivered lasting value for customers in financial services, government and beyond. It also speaks to our relentless pursuit of excellence across every sector we serve. By combining transformative technology with a forward-looking vision, we help our customers stay secure, competitive, and confident—especially as they navigate shifts like the rise of AI. This recognition is a testament to our people, our partners, and the culture of innovation and leadership that drives our continued success." Smarsh ranked No. 3437 on this year's list, reporting a three-year (2021–2024) revenue growth rate of 114%. The company's momentum is fueled by major innovations in compliance AI, including the industry's first solution for Microsoft Copilot Capture and an Intelligent Agent that applies cutting-edge AI to find risk in communications data efficiently. Smarsh supports a wide range of organizations, from emerging advisory firms to 18 of the top 20 global banks, helping them meet the requirements of the SEC, FINRA, and other regulators around the world. Execution That Delivers Results This recognition comes amid a year of strong momentum for Smarsh, marked by multiple accolades for its innovation, vision and culture. Recent honors include the 2025 Silver Globee Award for "Best Use of AI in Finance," a spot on the 2025 AIFINTECH100 list of the world's most innovative AI companies in financial services, and recognition as a 2025 USA TODAY Top Workplace. These accomplishments demonstrate leadership in delivering secure, scalable and future-ready solutions for the world's most regulated industries. "Making the Inc. 5000 is always a remarkable achievement, but earning a spot this year speaks volumes about a company's tenacity and clarity of vision," says Mike Hofman, editor-in-chief of Inc. "These businesses have thrived amid rising costs, shifting global dynamics, and constant change. They didn't just weather the storm—they grew through it, and their stories are a powerful reminder that the entrepreneurial spirit is the engine of the U.S. economy." For complete results of the Inc. 5000, visit About Smarsh Smarsh enables companies to transform oversight into foresight by surfacing business-critical signals in their digital communications. Serving the top banks, insurers, investment firms, and government agencies worldwide, Smarsh delivers cloud-native solutions that help organizations stay compliant, mitigate risk, and unlock the value of their communications data. Learn more at or follow us on LinkedIn. About Inc. Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit View source version on Contacts Media Contact press@ Sign in to access your portfolio
Yahoo
19 minutes ago
- Yahoo
ACHR: Archer Aviation Stock Tumbles as Q2 Loss Nearly Doubles
Aug 12 - Archer Aviation (NYSE:ACHR) shares slipped about 10% in premarket trading Tuesday after the electric aircraft maker posted a wider second-quarter loss. The company is still in the pre-revenue stage but is ramping up production for its electric vertical take-off and landing (eVTOL) aircraft, designed for urban transport. Warning! GuruFocus has detected 2 Warning Sign with ACHR. Adjusted expenses jumped 28% from a year ago to $123.5 million as Archer scaled up operations in California and Georgia. The company reported a Q2 net loss of $206 million, with an adjusted EBITDA loss of $118.7 million. That's significantly worse than Q2 2024's $106.9 million net loss and $93.8 million adjusted EBITDA loss. Looking ahead to Q3, Archer expects an adjusted EBITDA loss between $110 million and $130 million, compared to $93.5 million in the same period last year. CEO Adam Goldstein highlighted major milestones, including six Midnight aircraft in production, its selection as the official air taxi provider for the Los Angeles 2028 Olympics, and two defense program acquisitions. Archer also noted it has $1.7 billion in liquidity to support its growth ambitions. This article first appeared on GuruFocus.


Business Wire
21 minutes ago
- Business Wire
Techcyte and Modella AI Announce a Research Collaboration with Modella AI's State-of-the-Art Agentic and Generative AI-Powered Diagnostic Pathology Platform
OREM, Utah--(BUSINESS WIRE)-- Techcyte, a leading provider of AI-powered digital diagnostics for anatomic and clinical pathology, today announced that its platform, Techcyte Fusion ™ (research use only (RUO) in the US, CE-IVDD-marked in Europe), now includes Modella AI, a biomedical artificial intelligence company at the forefront of computational pathology, as a partner in the Techcyte Fusion Partner Program. This collaboration brings together Modella AI's groundbreaking research-use only AI co-pilot for pathologists, PathChat ™, with Techcyte's integrated, cloud-based digital pathology platform—supporting the advancement of workflow efficiency and expanding access to advanced AI-powered pathology tools for research. 'Modella AI's commitment to innovation, including agentic AI, and Techcyte's unified pathology platform create a powerful research combination,' said Matt Smith, Chief Strategy Officer at Techcyte. Modella AI is a biomedical artificial intelligence company focused on improving pathology through generative and agentic AI. Its flagship research product, PathChat, enables intelligent interactions with digital slides—offering capabilities such as report summarization, image interpretation, and contextual question answering. An advanced research-use only version of the tool, PathChat DX, has been granted U.S. Food and Drug Administration Breakthrough Device Designation, reflecting the device's potential to provide a more effective diagnosis of a life-threatening or irreversibly debilitating condition. While this designation recognizes the potential of the technology, any use of PathChat within the Techcyte Fusion platform remains for research use only and is not intended for clinical diagnostic purposes. 'Modella AI's commitment to innovation, including agentic AI, and Techcyte's unified pathology platform create a powerful research combination,' said Matt Smith, Chief Strategy Officer at Techcyte. 'Together, our goal is delivering practical AI that pathologists can trust and that seamlessly integrates into their digital workflows.' 'We're excited to partner with Techcyte to bring our pathology-native AI to a broader research audience,' said Jill Stefanelli, President, Cofounder, and Chief Executive Officer at Modella AI. 'Integrating PathChat into the Fusion research platform supports the exploration of AI-assisted workflows in pathology and reflects our shared commitment to advancing digital innovation in the lab.' The integration of PathChat into Techcyte Fusion represents a significant step forward in operationalizing next-generation AI. As pathology workloads increase and case complexity grows, this collaboration represents an important step toward exploring AI capabilities in digital pathology research settings—all within the familiar Techcyte platform. For more information about the Techcyte Fusion Partner Program, visit About Techcyte Techcyte is aiming to transform the practice of pathology through a unified, AI-powered digital platform that streamlines complex workflows, integrates with core lab systems, and enhances communication across the lab. By partnering with leading laboratories, scanner manufacturers, diagnostic hardware providers, and AI developers, we deliver a unified digital pathology platform to labs and clinics around the world, furthering our mission to positively impact the health of humans, animals, and the environment. Visit for more information. Techcyte's anatomic and clinical pathology platform is for Research Use Only in the United States. About Modella Modella AI ( is a Boston-based biomedical AI company dedicated to advancing healthcare through the development of cutting-edge generative and agentic AI technologies. By combining expertise in artificial intelligence and pathology, Modella AI aims to deliver innovative solutions that empower clinicians, improve patient outcomes, and transform medical workflows. Disclaimer: PathChat ™, PathChat ™ DX and the Techcyte Fusion ™ platform are research-use only devices and are not commercially available in the United States (as they are not FDA cleared or approved). The Techcyte Fusion platform is commercially available in Europe for diagnostic use. The FDA Breakthrough Device Designation for PathChat DX does not imply FDA clearance or approval. This press release contains forward-looking statements based on current assumptions and forecasts. Modella AI and Techcyte assume no obligation to update these statements to reflect future events or developments.